TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07891533: A Phase 2 Study of the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Epetraborole Tablets for the Treatment of Adults With Phlebotomy-Dependent Polycythemia Vera

Sponsor: AN2 Therapeutics, Inc · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 75 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07891533 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07891533 Rescue Dossier →